Suggested Readings

2023 Alzheimer’s disease facts and figures.

Alzheimer’s Association.

The Alzheimer's disease clinical spectrum: diagnosis and management.

Atri A. Med Clin North Am. 2019;103(2):263-293.

Apoe4 is a risk factor and potential therapeutic target for Alzheimer's disease.

Ayyubova G. CNS Neurol Disord Drug Targets. 2023. [Epub ahead of print]

Neuropathological stageing of Alzheimer-related changes.

Braak H, Braak E. Acta Neuropathol. 1991;82(4):239-259.

Biomarkers for the diagnosis of Alzheimer's disease in clinical practice: the role of CSF biomarkers during the evolution of diagnostic criteria.

Dulewicz M, Kulczyńska-Przybik A, Mroczko P, et al. Int J Mol Sci. 2022;23(15):8598.

The probabilistic model of Alzheimer disease: the amyloid hypothesis revised.

Frisoni GB, Altomare D, Thal DR, et al. Nat Rev Neurosci. 2022;23(1):53-66.

A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers.

Jack CR Jr, Bennett DA, Blennow K, et al. Neurology. 2016;87(5):539-547.

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.

Jack CR, Jr., Bennett DA, Blennow K, et al. Alzheimers Dement. 2018;14(4):535-562.

Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer's disease: a systematic review.

Jeremic D, Jiménez-Díaz L, Navarro-López JD. Ageing Res Rev. 2021;72:101496.

Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?

Leng F, Edison P. Nat Rev Neurol. 2021;17(3):157-172.

Development of Alzheimer's disease biomarkers: from CSF- to blood-based biomarkers.

Mankhong S, Kim S, Lee S, et al. Biomedicines. 2022;10(4):850.

Plasma biomarkers of alzheimer's disease: a review of available assays, recent developments, and implications for clinical practice.

Pais MV, Forlenza OV, Diniz BS. J Alzheimers Dis Rep. 2023;7(1):355-380.

Increasing precision of clinical diagnosis of Alzheimer's disease using a combined algorithm incorporating clinical and novel biomarker data.

Sabbagh MN, Lue LF, Fayard D, Shi J. Neurol Ther. 2017;6(suppl 1):83-95.

Donanemab in Early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial.

Sims JR, Zimmer JA, Evans CD, et al. JAMA. 2023;330(6):512-527.

Astrocytic and microglial cells as the modulators of neuroinflammation in Alzheimer’s disease.

Singh D. J Neuroinflammation. 2022;19(1):206.

The central role of tau in Alzheimer's disease: from neurofibrillary tangle maturation to the induction of cell death.

Thal DR, Tomé SO. Brain Res Bull. 2022;190:204-217.

Lecanemab in early Alzheimer’s disease.

van Dyck CH, Swanson CJ, Aisen P, et al. N Engl J Med. 2023;388(1):9-21.

Related activities

Improving Alzheimer’s Disease Management

Updates on Patient Diagnosis and Treatment

Faculty: Douglas Galasko, MD; Marwan N. Sabbagh, MD, FAAN
Release: 01/31/2024
Expiration: 01/31/2025